NCT01281527 – A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics Posted on November 27, 2018 by tsuperadmin -
NCT01081769 – A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia Posted on November 27, 2018 by tsuperadmin -
NCT01157351 – A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated Posted on November 27, 2018 by tsuperadmin -
NCT00249223 – Risperidone Depot (Microspheres) vs. Risperidone Tablets – a Non-inferiority, Efficacy Trial in Subjects With Schizophrenia Posted on March 8, 2018 by tsuperadmin -
NCT00645307 – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS® Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia – Open Label Phase Posted on July 18, 2016 by tsuperadmin -
NCT00105326 – A Double-blind, Placebo-controlled, Randomized Study Evaluating the Effect of Paliperidone ER Compared With Placebo on Sleep Architecture in Subjects With Schizophrenia Posted on March 31, 2016 by tsuperadmin -
NCT00524043 – A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia Posted on March 31, 2016 by tsuperadmin -
NCT01662310 – Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Posted on March 31, 2016 by tsuperadmin -
NCT01529515 – A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects With Schizophrenia Posted on March 31, 2016 by tsuperadmin -
The safety and efficacy of risperidone 8 mg qd and 4 mg qd compared to placebo in the treatment of schizophrenia Posted on March 31, 2016 by tsuperadmin -